Pregnancy induces profound physiological adaptations across nearly every organ system. Among the most common otorhinolaryngological changes is nasal congestion, affecting an estimated 20% to 40% of pregnant individuals, with prevalence peaking in the second trimester. Despite its frequency, pregnancy-related congestion is often trivialized as a minor inconvenience. However, severe cases can significantly impair quality of life, disrupt sleep, contribute to snoring and obstructive sleep apnea (OSA), and affect maternal blood pressure regulation. Understanding the distinction between benign ROP and other causes of congestion is critical for appropriate management.
| Medication Class | Examples | Safety Profile | Recommendation | | :--- | :--- | :--- | :--- | | | Budesonide (Pregnancy Cat B), Fluticasone (Cat C) | Minimal systemic absorption; budesonide has most reassuring safety data. | First-line pharmacotherapy for moderate-severe ROP. | | Intranasal Antihistamines | Azelastine (Cat C) | Limited systemic absorption; preferred over oral antihistamines. | Second-line, especially if allergic component suspected. | | Oral Antihistamines (non-sedating) | Loratadine, Cetirizine (Cat B) | Large post-marketing studies show no increased teratogenic risk. | Second-line for those with concurrent allergic rhinitis. | | Intranasal Cromolyn | Cromolyn sodium (Cat B) | Extremely safe, but requires frequent dosing (4-6x/day). | Third-line or adjunctive. | | Topical Decongestants | Oxymetazoline (Cat C) | Avoid prolonged use (>3 days) due to rhinitis medicamentosa; short-term use (1-2 days) only for severe obstruction. | Rescue only ; not for routine management. | | Oral Decongestants | Pseudoephedrine (Cat C) | Avoid in first trimester (theoretical risk of gastroschisis with first-trimester exposure); contraindicated with hypertension or preeclampsia. | Avoid unless severe and under physician guidance. | pregnancy and congestion
The Physiology and Management of Nasal Congestion in Pregnancy: A Review of "Rhinitis of Pregnancy" However, severe cases can significantly impair quality of
Nasal congestion is a common yet frequently underappreciated symptom during pregnancy. While often attributed to coincidental viral infections or allergies, a distinct entity known as "rhinitis of pregnancy" (ROP) exists, characterized by nasal obstruction in the absence of other infectious or allergic triggers. This paper reviews the epidemiological evidence, explores the multifactorial pathophysiology driven by hormonal fluctuations (estrogen, progesterone, and placental growth hormone) and increased plasma volume, discusses the clinical presentation and differential diagnosis, and provides evidence-based guidelines for safe management during gestation and lactation. | First-line pharmacotherapy for moderate-severe ROP
Pregnancy induces profound physiological adaptations across nearly every organ system. Among the most common otorhinolaryngological changes is nasal congestion, affecting an estimated 20% to 40% of pregnant individuals, with prevalence peaking in the second trimester. Despite its frequency, pregnancy-related congestion is often trivialized as a minor inconvenience. However, severe cases can significantly impair quality of life, disrupt sleep, contribute to snoring and obstructive sleep apnea (OSA), and affect maternal blood pressure regulation. Understanding the distinction between benign ROP and other causes of congestion is critical for appropriate management.
| Medication Class | Examples | Safety Profile | Recommendation | | :--- | :--- | :--- | :--- | | | Budesonide (Pregnancy Cat B), Fluticasone (Cat C) | Minimal systemic absorption; budesonide has most reassuring safety data. | First-line pharmacotherapy for moderate-severe ROP. | | Intranasal Antihistamines | Azelastine (Cat C) | Limited systemic absorption; preferred over oral antihistamines. | Second-line, especially if allergic component suspected. | | Oral Antihistamines (non-sedating) | Loratadine, Cetirizine (Cat B) | Large post-marketing studies show no increased teratogenic risk. | Second-line for those with concurrent allergic rhinitis. | | Intranasal Cromolyn | Cromolyn sodium (Cat B) | Extremely safe, but requires frequent dosing (4-6x/day). | Third-line or adjunctive. | | Topical Decongestants | Oxymetazoline (Cat C) | Avoid prolonged use (>3 days) due to rhinitis medicamentosa; short-term use (1-2 days) only for severe obstruction. | Rescue only ; not for routine management. | | Oral Decongestants | Pseudoephedrine (Cat C) | Avoid in first trimester (theoretical risk of gastroschisis with first-trimester exposure); contraindicated with hypertension or preeclampsia. | Avoid unless severe and under physician guidance. |
The Physiology and Management of Nasal Congestion in Pregnancy: A Review of "Rhinitis of Pregnancy"
Nasal congestion is a common yet frequently underappreciated symptom during pregnancy. While often attributed to coincidental viral infections or allergies, a distinct entity known as "rhinitis of pregnancy" (ROP) exists, characterized by nasal obstruction in the absence of other infectious or allergic triggers. This paper reviews the epidemiological evidence, explores the multifactorial pathophysiology driven by hormonal fluctuations (estrogen, progesterone, and placental growth hormone) and increased plasma volume, discusses the clinical presentation and differential diagnosis, and provides evidence-based guidelines for safe management during gestation and lactation.
